Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$49.0 million.

  • Celldex Therapeutics' Free Cash Flow rose 1223.47% to -$49.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$181.7 million, marking a year-over-year decrease of 1379.65%. This contributed to the annual value of -$159.7 million for FY2024, which is 4638.48% down from last year.
  • According to the latest figures from Q3 2025, Celldex Therapeutics' Free Cash Flow is -$49.0 million, which was up 1223.47% from -$44.7 million recorded in Q2 2025.
  • Celldex Therapeutics' Free Cash Flow's 5-year high stood at -$12.1 million during Q2 2021, with a 5-year trough of -$55.9 million in Q3 2024.
  • Over the past 5 years, Celldex Therapeutics' median Free Cash Flow value was -$29.2 million (recorded in 2023), while the average stood at -$30.8 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 4611.25% in 2023, then crashed by 19181.2% in 2024.
  • Quarter analysis of 5 years shows Celldex Therapeutics' Free Cash Flow stood at -$14.9 million in 2021, then crashed by 47.86% to -$22.0 million in 2022, then plummeted by 50.93% to -$33.2 million in 2023, then dropped by 0.17% to -$33.3 million in 2024, then plummeted by 47.49% to -$49.0 million in 2025.
  • Its Free Cash Flow stands at -$49.0 million for Q3 2025, versus -$44.7 million for Q2 2025 and -$54.7 million for Q1 2025.